Adding AstraZeneca Plc's
(Get Free Alerts for AZN) Lynparza to Johnson & Johnson's (Get Free Alerts for JNJ) Zytiga (abiraterone) extended the time to live without disease progression in patients with newly diagnosed metastatic, castration-resistant prostate cancer (mCRPC) with or without homologous recombination repair (HRR) gene mutations.- The Lynparza combination pared down that risk by 34% over Zytiga alone, according to phase 3 data released at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).
- The Lynparza combo added more than eight months to patients' time to disease progression or death, reaching a median of 24.8 months versus 16.6 months for the control group.
- AZ and Merck designed the 796-patient phase 3 PROpel trial for all patients independent of HRR status.
- Results also showed a favorable trend towards improved overall survival (OS) with Lynparza plus abiraterone versus abiraterone alone.
- However, the difference did not reach statistical significance at this data cut-off (analysis at 29% data maturity). The trial will continue to assess OS as a key secondary endpoint.
- In July 2017, AstraZeneca and Merck & Co Inc (NYSE: MRK) announced an oncology collaboration to co-develop and co-commercialize Lynparza and Koselugo (selumetinib) for multiple cancer types.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.